Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study by Elena Schiopu et al.
Schiopu et al. Arthritis Research & Therapy  (2016) 18:131 
DOI 10.1186/s13075-016-1021-2RESEARCH ARTICLE Open AccessSafety and tolerability of an anti-CD19
monoclonal antibody, MEDI-551, in subjects
with systemic sclerosis: a phase I,
randomized, placebo-controlled, escalating
single-dose study
Elena Schiopu1*, Soumya Chatterjee2, Vivien Hsu3, Armando Flor4, Daniel Cimbora4, Kaushik Patra4, Wenliang Yao4, Jing Li5,
Katie Streicher4, Kathleen McKeever4,6, Barbara White4,7, Eliezer Katz4, Jorn Drappa4, Sarah Sweeny4 and Ronald Herbst4Abstract
Background: Systemic sclerosis (SSc) is a clinically heterogeneous, life-threatening disease characterized by fibrosis,
microvasculopathy, and autoimmunity. Extensive nonclinical and clinical data implicate B cells in the pathogenesis
of SSc. MEDI-551 is an investigational humanized monoclonal antibody that targets the B cell surface antigen CD19
and mediates antibody-dependent, cell-mediated cytotoxicity of B cells. This clinical study evaluated the safety and
tolerability, pharmacokinetics, and pharmacodynamics of MEDI-551 in subjects with SSc.
Methods: This phase I multicenter, randomized, double-blind, placebo-controlled, single escalating dose study
enrolled adult subjects with either limited or diffuse cutaneous SSc. A single intravenous dose of MEDI-551 was
administered, and safety and tolerability were evaluated. MEDI-551 pharmacokinetics (PK), pharmacodynamics, and
immunogenicity were also assessed. Safety assessments included the incidence of adverse events and changes in
clinical and laboratory results. MEDI-551 serum concentrations, effects on circulating and tissue B cells and plasma
cells (PCs), and antidrug antibodies were analyzed. Modified Rodnan skin score (MRSS) and pulmonary function
tests were used to explore the clinical effect of MEDI-551.
Results: The study enrolled 28 subjects with SSc (mean age, 47.3 years; 67.9 % female). Twenty-four received a single
dose of MEDI-551 (0.1–10.0 mg/kg) and four received placebo. Treatment-emergent adverse events (TEAEs) occurred in
95.8 % of subjects in the MEDI-551 group and in 75.0 % of subjects in the placebo group; the majority of TEAEs were
mild or moderate in severity. Two serious adverse events were considered possibly related to the study drug. One death,
deemed not related to the study drug, occurred in a MEDI-551-treated subject. MEDI-551 exhibited linear PK in the dose
range of 1.0 to 10.0 mg/kg, and more rapid clearance at lower doses. Dose-dependent depletion of circulating B cells and
plasma cells was observed. MRSS assessments suggest a possible clinical effect of MEDI-551 on affected skin.
Conclusions: A single escalating dose of MEDI-551 was tolerable and safe in this subject population. B cell depletion was
achieved and was dose dependent. A signal of clinical effect was observed. Based on these results, further investigation of
MEDI-551 as a disease-modifying treatment for SSc is warranted.
Trial registration: www.clinicaltrials.gov identifier, NCT00946699; registered 23 July 2009.
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Systemic sclerosis (SSc), a connective tissue disorder, is
characterized by autoimmune processes, obliterative
microvasculopathy, and fibrosis that affects the skin and
internal organs [1, 2]. Disease manifestations are highly
heterogeneous and include digital vasculopathy, variable
degrees of skin and musculoskeletal involvement, inter-
stitial and vascular lung disease, scleroderma renal crisis,
and gastrointestinal disease. Patients with SSc experience
a substantial increase in mortality, and there is a lack of
effective therapeutic options for these patients [3–5].
Clinical and animal study data suggest a pathogenic
role of B cell activation and autoantibody production in
SSc, identifying B cells as a promising target for thera-
peutic intervention [6–10]. B cell and plasma cell (PC)
infiltrates have been reported in affected skin and lung
tissue obtained from patients with SSc [11–15]. B cells
found in SSc patients are highly active, as evidenced by
hypergammaglobulinemia, polyclonal B cell hyperactiv-
ity, and the presence of autoantibodies [16, 17]. En-
hanced B cell signaling in SSc patients is associated with
increased production of profibrotic cytokines, such as
interleukin (IL)-6 and transforming growth factor
(TGF)-β [18, 19]. A wide variety of SSc-associated auto-
antibodies produced by plasma cells have been identified in
patients; several are associated with particular clinical pic-
tures and prognoses, and there is evidence for the involve-
ment of certain autoantibodies in the pathogenic processes
of fibrosis and vasculopathy underlying SSc [8, 20].
Several clinical studies examined the effects of the B
cell-depleting agent rituximab, an anti-CD20 antibody, in
patients with SSc. Positive effects on skin thickness and
pulmonary function were reported and, in some studies, a
significant effect (p ≤ 0.01) was achieved [11, 12, 21–23].
Clearly, more data, particularly from well-designed, ran-
domized, double-blind, placebo-controlled clinical studies,
are needed to understand the potential for B cell depletion
as a therapeutic avenue in SSc.
The B cell surface antigen CD19 is expressed through-
out B cell development, from pre-B cells through plas-
mablasts and in some plasma cells. CD19, a key positive
regulator of B cell signaling, is overexpressed in SSc pa-
tients, and even modest overexpression of CD19 in
transgenic mice induced production of SSc-associated
autoantibodies [24]. A novel B cell-depleting agent,
MEDI-551 (MedImmune; Gaithersburg, MD, USA) tar-
gets CD19 and is a humanized, afucosylated immuno-
globulin (Ig)G1k monoclonal antibody with enhanced
affinity for the human FcγRIIIA and murine FcγRIV re-
ceptors. MEDI-551 mediates antibody-dependent cellu-
lar cytotoxicity (ADCC) targeting B cells in vitro and in
transgenic mice that express human CD19 [25, 26]. In a
murine model of experimental SSc, wherein production
of pathogenic autoantibodies requires CD19+ B cells,MEDI-551 was effective in reducing circulating and tar-
get tissue-infiltrating B cells, total serum immunoglobu-
lin, autoantibodies, and deposition of complement
proteins in target tissues. Furthermore, the benefit to or-
gans affected by SSc was evident in those mice with kid-
ney pathology, wherein treatment with MEDI-551
induced sustained reversion of proteinuria and reduction
of Ig deposition in glomeruli (Tracy Delaney, written
communication, May 2009).
This phase I clinical study of MEDI-551 in subjects
with SSc was designed to assess the safety and tolerabil-
ity, pharmacokinetics (PK), pharmacodynamics (PD),
and immunogenicity of MEDI-551, and to explore po-
tential activity of MEDI-551 on SSc disease measures.
Methods
Study design
This phase I, multicenter, randomized, double-blind,
placebo-controlled dose escalation study of a single
intravenous (IV) dose of MEDI-551 enrolled adult sub-
jects with SSc. The primary objective was to evaluate the
safety and tolerability of MEDI-551 in adults with SSc.
Secondary objectives included evaluation of the PK, PD,
and immunogenicity of MEDI-551. Assessing possible
effects of MEDI-551 on measures of disease activity and
disease-relevant biomarkers were exploratory end points.
The study was conducted in accordance with the
Declaration of Helsinki, International Council for Harmon-
isation Guidance for Good Clinical Practice, and all local
laws (www.clinicaltrials.gov identifier: NCT00946699). The
ethics committee from each participating hospital approved
the study protocol and all amendments (IRB numbers:
HUM00040791 and HUM00031527; see Appendix). All
subjects provided written informed consent before study
participation.
Following a screening period of up to 21 days, the inves-
tigator or designee entered eligible subjects’ names and
relevant information into an interactive voice-response
system (IVRS). The IVRS then assigned subjects in a 6:1
ratio (except for groups 1 [n = 1] and 2 [4:1]) to one of five
ascending-dose groups. Subjects received a single IV dose
of MEDI-551 or placebo on day 1 (Fig. 1). Study site
personnel and subjects were blinded to treatment; the
study sponsor’s staff members were not blinded. MEDI-
551 was administered over ≥60 minutes for doses up to
1 mg/kg, and over ≥120 minutes for doses >1 mg/kg. As-
sessments for safety, PK, and PD took place at scheduled
visits over the 12-week posttreatment period (days 1, 3,
15, 29, 57, and 85). Dose-escalation decisions were made
no earlier than day 29 and were based on the incidence of
treatment-emergent adverse events (TEAEs), serious ad-
verse events (SAEs), and safety laboratory data.
Subjects with reduced B cell counts at day 85 were eli-
gible to enter a long-term follow-up (LTFU) period,
Fig. 1 Study design. Number of subjects in each group includes those who received MEDI-551 and those who received placebo. LTFU
long-term follow-up
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every 3 months thereafter for safety evaluations and B
cell assessment. Early versions of the protocol specified
that subjects in whom B cell counts had not returned to
≥25 % of the baseline value or ≥50 % of the lower limit
of normal (LLN) at day 85 were eligible to participate in
the LTFU period. During the study, the protocol was
amended to include in the LTFU any subject whose B
cell count on day 85 was lower than on day 1, in
response to feedback from the US Food and Drug
Administration to more fully characterize B cell reple-
tion. Subjects who completed the study under earlier
versions of the protocol were asked to re-enter the study
and consent to blood sampling. This included two sub-
jects who had received placebo. Subjects were followed
over the LTFU period until B cell counts were at least
equal to baseline values. The investigator and medical
monitor were permitted to conjointly decide to discon-
tinue LTFU if baseline B cell counts were reached in a
subject after 18 months.
Subjects in the first three dose groups did not receive
prophylactic premedication for the prevention of
infusion-related reactions (IRRs). Following the occur-
rence of a grade 3 IRR in the first subject in the MEDI-
551 3.0-mg/kg group, the remaining subjects received
oral acetaminophen 500 to 600 mg, oral diphenhydra-
mine 25 to 50 mg, and IV methylprednisolone 100 mg
or equivalent glucocorticoid 30 to 60 minutes before
study drug administration.
Subjects
Eligible subjects were aged at least 18 years, fulfilled the
College of Rheumatology/European League Against
Rheumatism classification criteria for SSc [2], had at
least moderate skin thickening (modified Rodnan skin
score [MRSS] [27] ≥2) in at least one area suitable for a
repeat skin biopsy, had B cell counts in peripheral blood
of ≥50 % LLN at screening, had forced vital capacity(FVC) of ≥55 % predicted and diffusing capacity for car-
bon monoxide (DLco) of ≥40 % predicted. Subjects were
not eligible if they had pulmonary hypertension requiring
treatment, scleroderma renal crisis within the previous
year, significant malabsorption, Herpes zoster infection in
the previous 3 months, a history of severe viral infection,
active hepatitis or human immunodeficiency virus (HIV)
infection, or evidence of active or latent tuberculosis with-
out appropriate treatment.
Safety evaluations
Adverse events (AEs) and serious AEs (SAEs) were re-
corded through study exit. Investigators determined the
severity of AEs (according to the National Cancer Insti-
tute Common Terminology Criteria for Adverse Events
version 4.0 criteria) and their causal relationship to the
study drug. Vital signs were measured at each visit from
day 1 to day 85. Physical examinations were performed
on days 1 and 85. Samples for clinical laboratory tests
(serum chemistry, hematology, and urinalysis) were col-
lected at each visit through day 85, except for day 3.
Electrocardiograms (ECGs) were obtained on days 3 and
85. Samples for IgM, IgG, IgA, and IgE levels were ob-
tained on days 29 and 85, and during the LTFU period.
Clinical laboratory safety tests, including those used in
screening, were conducted by a central laboratory.
Throughout the study, a Safety Monitoring Committee
comprising physicians, some employed by MedImmune,
met monthly and ad hoc to independently review cumu-
lative safety surveillance data and the medical monitor’s
decisions on dose escalation, and to make recommenda-
tions regarding study progression.
Immunogenicity evaluations
The presence of antidrug antibodies (ADAs) was evalu-
ated in blood samples collected prior to dosing on day 1,
on days 29, 57, and 85, and during the B cell LTFU
period. An electrochemiluminescent, solution-phase,
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Meso Scale Diagnostics (Rockville, MD, USA) was devel-
oped and validated by MedImmune for the detection,
confirmation, and titration of ADAs to MEDI-551 in hu-
man serum. Study samples that tested positive for ADAs
and were confirmed in a screening assay were then ana-
lyzed in a titration assay, wherein samples were serially
diluted with negative control serum and the highest di-
lution with detectable ADAs was determined. Subjects
were considered to be positive for ADAs if ADAs were
detected in the titration assay at sample dilutions ≥1:50.
Pharmacokinetic evaluations
Blood samples for PK analysis were collected before in-
fusion and 30 minutes after the end of infusion on day
1, and on days 3, 8, 15, 29, 57, and 85. MEDI-551 con-
centration was measured in human serum samples using
a colorimetric sandwich enzyme-linked immunosorbent
assay (ELISA) developed and validated by MedImmune.
The upper and lower limits of quantification were deter-
mined to be 4105 ng/mL and 100 ng/mL, respectively.
Method validation met the acceptance criteria for accur-
acy, precision, selectivity (evaluated in serum from nor-
mal individuals and in serum samples from subjects with
scleroderma), specificity, dilutional linearity, robustness,
and stability of MEDI-551 in human serum.
Pharmacodynamic evaluations
Peripheral blood samples for B cell analysis were col-
lected prior to dosing on day 1, and on days 3, 8, 15, 29,
57, and 85. For subjects who entered the LTFU period,
blood samples for B cell analysis were collected once
monthly for 3 months then every 3 months thereafter,
until counts returned to baseline (day 1) values. The
presence of MEDI-551 in samples interferes with CD19-
based detection of B cells by flow cytometry. Therefore,
immunodetection of the B cell surface marker CD20,
which is co-expressed with CD19 on B cells throughout
most of their development, was used to monitor B cells
by flow cytometry following MEDI-551 treatment. The
absolute number of CD20+ B cells per microliter was
derived from the percentage of CD20+ cells and the ab-
solute number of lymphocytes. The absolute number of
lymphocytes was calculated using white blood cell
counts and total number of CD45+ cells. Flow cytometry
was performed at two central laboratory facilities
(LabCorp; Cranford, NY, USA and Mechelen, Belgium).
The plasma cell (PC) gene signature was previously
described as a robust, sensitive, and accurate measure of
PCs in clinical samples [28]. The PC gene signature is
based on expression analysis of five genes (IGHA1, IGJ,
IGKC, IGKV4-1, and TNFRSF17) expressed predomin-
antly in PCs. The PC gene signature was evaluated by
whole-genome microarray in blood samples obtained ondays 1, 3, 29, and 85, and during the LTFU period. For
each subject at each time point after day 1, the PC gene
signature was calculated as the median of the percentage
change from baseline of the genes in each panel, and is
interpreted as a change in PC abundance.Disease assessments
The MRSS, a validated measure of SSc disease activity in
skin [29], is a clinician-rated assessment of skin thickness
at 17 body sites, including the fingers, hands, forearms,
arms, face, chest, abdomen, thighs, legs, and feet, with each
site scored from 0 to 3 (0 = normal skin, 1 =mild thick-
ness, 2 =moderate thickness, and 3 = severe thickness).
The MRSS is the sum of scores at all 17 sites, for a max-
imum score of 51. The MRSS is responsive to therapeutic
intervention, and a change of 3 to 5 points was found to
be the minimum clinically significant difference [30].
Pulmonary function tests to measure FVC and DLco
[31, 32] were performed according to the guidelines of the
American Thoracic Society and European Respiratory
Society [33] at screening and on days 29 and 85, and the
percentage of predicted normal values was calculated.Statistical analyses
Sample size determination was based on typical design
of a phase I study. A minimum of 27 subjects were
planned for enrollment, with a maximum of 35 subjects
if additional eligible subjects were available by closure of
enrollment. Results were presented descriptively (no for-
mal statistical hypothesis testing) for the as-treated
population (i.e., subjects who received ≥1 dose of study
drug) by actual treatment received. Treatment-emergent
AEs were defined as those with onset immediately
following study drug administration through end of
study, and were coded using the Medical Dictionary for
Regulatory Activities, version 17.0.
Noncompartmental PK data analyses were performed,
with time 0 defined as the beginning of the infusion.
Postdose maximum observed concentration (Cmax), area
under the concentration-time curve from dosing to the
last measurable time point (AUClast), postdose AUC ex-
trapolated to infinity (AUCinf ), systemic clearance (CL),
elimination half-life (t½), and steady-state volume of dis-
tribution (Vss) were determined. The incidence of detect-
able ADAs was summarized by treatment group.
For analysis of the PD effect of MEDI-551 on periph-
eral B cells, B cell depletion was defined as a reduction
in B cell counts by ≥90 % from day 1 values. Time to de-
pletion was defined as the time to the first observation
of ≥90 % reduction from baseline in B cell counts in a
subject, and duration of depletion was defined as the
interval between first and last observations of ≥90 % re-
duction from day 1 values in B cell counts in a subject.
Schiopu et al. Arthritis Research & Therapy  (2016) 18:131 Page 5 of 14Results
Subjects
The study enrolled 28 subjects at 13 sites in the US, UK,
and Canada and was conducted from 19 March 2010 to
19 March 2014 (Fig. 2). Group 1 consisted of a single sub-
ject who received MEDI-551 0.1 mg/kg. Groups 2 through
5 each comprised four to seven subjects, randomized to
receive increasing doses of MEDI-551 or placebo. In total,
24 subjects received MEDI-551 and four subjects received
placebo. All subjects received a single dose of study drug
according to their assigned treatment. All 28 subjects
remained on study through day 85, and 24 subjects en-
tered the LTFU period for B cell monitoring. Reasons for
discontinuation included lost to follow-up (one subject in
the placebo group), withdrawal of consent (one subject in
the 1-mg/kg group, one subject in the 3-mg/kg group),
and death (one subject in the 3-mg/kg group).
Demographics and baseline characteristics were sum-
marized for the entire study population and by treatment
group (Table 1). Overall, the clinical and other baseline
characteristics, including B cell counts, were similar be-
tween treatment groups. The overall study population was
predominantly female (67.9 %) and white (85.7 %), with a
mean age of 47.3 years. Most subjects (85.7 %) were diag-
nosed with diffuse cutaneous (as opposed to limited cuta-
neous) SSc, and mean disease duration was 5.4 years from
onset of non-Raynaud’s symptoms. Most subjects (75.0 %)
were positive for antinuclear autoantibodies. The study
subjects had skin thickening (mean MRSS, 23.0) and
mildly reduced lung function (mean 82.5 % predicted
FVC; mean 72.0 % predicted DLco) at baseline.
Safety
The majority of subjects in the combined MEDI-551
group (n = 23 [95.8 %]) and in the placebo group (n = 3Fig. 2 Subject disposition[75.0 %]) experienced ≥1 TEAE during the study
(Table 2). The majority of TEAEs (111/127 events
[87.4 %]) reported by MEDI-551-treated subjects were
mild or moderate (grade 1 or 2) in severity. In the
MEDI-551 group, seven subjects (29.2 %) experienced a
grade 3 TEAE (14 events) and one subject (4.2 %) expe-
rienced a grade 4 TEAE (one event). No subject in the
placebo group experienced a TEAE worse than grade 2
(14 events total).
The most frequent TEAEs (regardless of relationship to
the study drug) were nausea (n = 4 [16.7 %], MEDI-551;
n = 0, placebo), fatigue (n = 4 [16.7 %], MEDI-551; n = 1
[25.0 %], placebo), IRRs (n = 4 [16.7 %], MEDI-551; n = 0,
placebo), arthralgia (n = 4 [16.7 %], MEDI-551; n = 1
[25.0 %], placebo), and pain in extremity (n = 4 [16.7 %],
MEDI-551; n = 1 [25.0 %], placebo). In the MEDI-551
group, 14 subjects (58 %) experienced a total of 20 TEAEs
that were considered by investigators to be related to the
study drug (Table 2). Most were single events, with the
exception of IRRs in four subjects and cough in two
subjects. No subjects in the placebo group experienced a
treatment-related TEAE.
In the MEDI-551 group, six subjects (25 %) experi-
enced a total of 15 SAEs. Of these, 13 events (atrial fib-
rillation, colitis, ischemic colitis, diarrhea, gastric antral
vascular ectasia, noncardiac chest pain, prostate cancer,
cervical myelopathy, acute renal failure, scleroderma
renal crisis, respiratory failure, and two occurrences of
skin ulcer) were considered to be not related to the
study drug. The two SAEs deemed possibly related to
the study drug were supraventricular tachycardia (grade
2, onset day 2, duration 1 day, occurring in a subject in
the MEDI-551 0.3-mg/kg group) and subclavian vein
thrombosis (grade 3, onset day 2, duration 27 days, oc-
curring in a subject in the MEDI-551 1.0-mg/kg group);
Table 1 Baseline characteristics of study subjects
Characteristic Placebo MEDI-551 (n = 24) Total
0.1 mg/kg 0.3 mg/kg 1.0 mg/kg 3.0 mg/kg 10 mg/kg
(n = 4) (n = 1) (n = 4) (n = 6) (n = 6) (n = 7) (N = 28)
Age, years, mean (SD) 42.3 (14.4) 52.0 (NA) 47.3 (11.6) 48.8 (9.8) 49.8 (9.3) 46.0 (8.6) 47.3 (9.7)
Female, n (%) 2 (50.0) 0 (0.0) 3 (75.0) 3 (50.0) 5 (83.3) 6 (85.7) 19 (67.9)
White, n (%) 4 (100.0) 1 (100.0) 2 (50.0) 6 (100.0) 5 (83.3) 6 (85.7) 24 (85.7)
Weight, kg, mean (SD) 84.7 (7.9) 114.2 (NA) 75.3 (4.4) 68.2 (18.7) 73.4 (14.6) 71.7 (20.5) 75.2 (17.1)
Diffuse cutaneous SSc, n (%) 3 (75.0) 1 (100.0) 3 (75.0) 5 (83.3) 6 (100.0) 6 (85.7) 24 (85.7)
Disease duration, years, mean (SD) 5.6 (6.2) 5.3 (NA) 5.7 (3.35) 6.7 (4.7) 3.7 (3.0) 5.4 (5.1) 5.4 (4.3)
Positive antinuclear antibody, n (%) 2 (50.0) 0 (0.0) 4 (100.0) 4 (66.7) 4 (66.7) 7 (100.0) 21 (75.0)
Positive anti-Scl70 antibody, n (%) 3 (75.0) 0 (0.0) 1 (25.0) 2 (33.3) 4 (66.7) 2 (28.6) 12 (42.9)
Elevated acute phase reactants (ESR, CRP), n (%) 2 (50.0) 1 (100.0) 1 (25.0) 4 (66.7) 3 (50.0) 3 (42.9) 14 (50.0)
MRSS, mean (SD) 22.8 (7.5) 31.0 (NA) 23.5 (7.6) 20.0 (9.8) 23.3 (12.8) 24.0 (5.1) 23.0 (8.5)
FVC, % predicted, mean (SD) 87.9 (10.9) 83.0 (NA) 87.0 (10.9) 75.0 (19.0) 83.8 (21.9) 82.1 (22.8) 82.5 (17.8)
DLco, % predicted, mean (SD) 69.8 (30.2) 98.0 (NA) 79.5 (20.9) 54.5 (10.0) 74.8 (29.2) 77.9 (20.7) 72.0 (23.1)
CD19 B cell count, cells/uL, mean (SD) 223.8 (209.5) 182.0 (NA) 187.3 (149.9) 119.2 (115.7) 175.8 (116.1) 175.3 (211.8) 172.3 (152.9)
CD20 B cell count, cells/uL, mean (SD) 221.0 (210.7) 174.0 (NA) 180.0 (135.3) 115.8 (113.9) 177.0 (116.5) 173.3 (211.4) 169.6 (151.3)
CRP C-reactive protein, DLco diffusing capacity for carbon monoxide, ESR erythrocyte sedimentation rate, FVC forced vital capacity, MRSS modified Rodnan skin
score, NA not available, SSc systemic scleroderma
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SAEs occurred in the placebo group.
One subject died on study. This subject, who had received
MEDI-551 3.0 mg/kg, experienced an SAE of scleroderma
renal crisis (onset day 62) that led to death 47 days later.
This subject also experienced SAEs of gastric antral vascular
ectasia (grade 3, onset day 62) and respiratory failure (grade
4, onset day 67). Both the investigator and the study spon-
sor assessed these events as not related to MEDI-551, with
an alternative etiology of underlying disease.
No subject experienced hypersensitivity (including
anaphylaxis), immune complex disease, cytopenia (neu-
tropenia, thrombocytopenia), or progressive multifocal
leukoencephalopathy. The TEAEs categorized as “infec-
tions and infestations” occurred at similar frequency in
the MEDI-551 (n = 11 [45.8 %]) and placebo (n = 2
[50.0 %]) groups; all were grade 1 or 2. Four out of 12
subjects (33.3 %) in the MEDI-551 group who were not
premedicated experienced an IRR. Three of these sub-
jects (two in the 1.0-mg/kg group and one in the 3.0-
mg/kg group) received reduced doses of MEDI-551 be-
cause of the IRR. All IRRs but one were grade 1 or grade
2 in severity, none were serious, all were treated with
antihistamine, anxiolytic, and/or analgesic medications,
and all resolved within 2 days. The one grade 3 IRR oc-
curred in a subject in the MEDI-551 3.0-mg/kg group,
which prompted the protocol amendment requiring pre-
medication to mitigate IRRs. After this protocol amend-
ment was implemented, none of the subsequent 12
subjects who received MEDI-551 experienced an IRR.
No subjects in the placebo group experienced an IRR.Analysis of IgG, IgA, IgM, and IgE levels revealed that,
in the total MEDI-551 group, seven subjects with nor-
mal baseline values had low posttreatment values. These
included two subjects with IgG values less than the nor-
mal range at day 85 and one subject with IgG values less
than the normal range at B cell recovery; one subject
with an IgA value less than the normal range at day 85
and one subject with an IgA value less than the normal
range at B cell recovery; and two subjects with IgM
values less than the normal range at days 29 and 85. No
subject in the placebo group with a normal baseline
value had a low posttreatment value.
Of the four subjects in the MEDI-551 group who ex-
perienced IRRs, vital sign abnormalities, including ele-
vated blood pressure, respiratory rate, or heart rate, were
reported on the day of infusion for three subjects; vital
signs were not collected on the day of infusion for the
fourth subject. One subject in the MEDI-551 0.3-mg/kg
group had an elevated heart rate on day 3 that was re-
ported as an SAE (supraventricular tachycardia) and was
assessed as possibly related to MEDI-551, although an
alternate etiology of preexisting supraventricular tachy-
cardia was provided.
Two subjects (8.3 %) in the MEDI-551 group had a
clinically significant abnormal ECG finding on day 3 that
was reported as a TEAE. A subject in the MEDI-551
0.3-mg/kg group with a history of supraventricular
tachycardia, hypertension, and palpitations experienced
an SAE of supraventricular tachycardia (onset day 2)
that persisted on day 3 and resolved after treatment with
metoprolol. A subject in the MEDI-551 10.0-mg/kg
Table 2 Treatment-emergent and treatment-related adverse events
Adverse event, n (%) Placebo MEDI-551
0.1 mg/kg 0.3 mg/kg 1.0 mg/kg 3.0 mg/kg 10 mg/kg Total
(n = 4) (n = 1) (n = 4) (n = 6) (n = 6) (n = 7) (N = 24)
≥1 TEAE 3 (75.0) 1 (100.0) 4 (100.0) 6 (100.0) 5 (83.3) 7 (100.0) 23 (95.8)
≥1 grade 3 TEAE 0 1 (100.0) 0 2 (33.3) 2 (33.3) 2 (28.6) 7 (29.2)
≥1 grade 4 TEAE 0 0 0 0 1 (16.7) 0 1 (4.2)
Death 0 0 0 0 1 (16.7) 0 0
≥1 SAE 0 1 (100.0) 1 (25.0) 1 (16.7) 2 (33.3) 1 (14.3) 6 (25.0)
≥1 study drug-related TEAE 0 0 2 (50.0) 4 (66.7) 4 (66.7) 4 (57.1) 14 (58.3)
≥1 study drug-related SAE 0 0 1 (25.0) 1 (16.7) 0 0 2 (8.3)
Treatment-related TEAEs and SAEs, by MedDRA preferred term
Infusion-related reaction 0 0 1 (25.0) 2 (33.3) 1 (16.7) 0 4 (16.7)
Cough 0 0 0 0 0 2 (28.6) 2 (8.3)
Diarrhea 0 0 0 0 1 (16.7) 0 1 (4.2)
Fatigue 0 0 0 0 0 1 (14.3) 1 (4.2)
Flushing 0 0 0 1 (16.7) 0 0 1 (4.2)
Headache 0 0 0 0 0 1 (14.3) 1 (4.2)
Hot flush 0 0 0 1 (16.7) 0 0 1 (4.2)
Hyperglycemia 0 0 0 0 1 (16.7) 0 1 (4.2)
Lip swelling 0 0 0 0 1 (16.7) 0 1 (4.2)
Night sweats 0 0 0 0 0 1 (14.3) 1 (4.2)
Rash 0 0 0 0 1 (16.7) 0 1 (4.2)
Subclavian vein thrombosis 0 0 0 1 (16.7) 0 0 1 (4.2)
Supraventricular extrasystoles 0 0 0 0 0 1 (14.3) 1 (4.2)
Supraventricular tachycardia 0 0 1 (25.0) 0 0 0 1 (4.2)
Tongue ulceration 0 0 0 0 0 1 (14.3) 1 (4.2)
Upper respiratory tract infection 0 0 0 0 1 (16.7) 0 1 (4.2)
MedDRA Medical Dictionary for Regulatory Activities, SAE serious adverse event, TEAE treatment-emergent adverse event,
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pulmonary hypertension experienced a TEAE of supra-
ventricular extrasystoles (onset day 2) and had an abnor-
mal, clinically significant ECG finding of premature
supraventricular complexes on day 3. No subject in the
placebo group had a clinically significant abnormal ECG
finding before or after dosing.
Immunogenicity
No subjects were positive for anti-MEDI-551 ADAs
prior to dosing, nor were any subjects in the placebo
group positive at any time after dosing. Among subjects
who received MEDI-551, four (16.7 %) were found to be
positive at one or more time points after dosing, with no
apparent relationship to dose level (one subject in the
0.3-mg/kg group, one in the 1-mg/kg group, one in the
3-mg/kg group, and one in the 10-mg/kg group). The
subjects in the MEDI-551 0.3- and 1.0-mg/kg groups
were positive for ADAs on days 29, 57, and 85, and were
negative thereafter. The subject in the MEDI-551 3.0-mg/kg group was positive on days 29 and 57; no further
data were available. The subject in the MEDI-551 10.0-
mg/kg group was positive on day 29, negative on days
57 and 85, and became positive again on day 365, with
no further data available.
Of the four ADA-positive subjects, two (one in the
0.3-mg/kg group and one in the 10.0-mg/kg group) re-
ceived the full dose of MEDI-551, and two (one in the
1.0-mg/kg group and one in the 3.0-mg/kg group) re-
ceived a reduced dose (90.0 % and 39.7 % of the
intended doses, respectively) owing to the occurrence of
an IRR. In the two subjects who received full doses,
MEDI-551 serum concentration-time profiles were simi-
lar to those of other members of the respective dose
group. In the two subjects who received a reduced dose,
serum concentration-time profiles were less than other
members of the dose group. The ADA-positive subjects
in the MEDI-551 0.3-mg/kg and 10.0-mg/kg groups who
received full MEDI-551 doses and the subject in the
MEDI-551 1.0-mg/kg group who received 90 % of the
Schiopu et al. Arthritis Research & Therapy  (2016) 18:131 Page 8 of 14intended dose displayed B cell depletion patterns similar
to those of other members of their respective groups.
The ADA-positive subject in the MEDI-551 3.0-mg/kg
group who received 39.7 % of the intended dose showed
evidence of reduced B cell depletion relative to other
members of the group.
Pharmacokinetics
MEDI-551 serum concentration-time profiles following
a single IV administration of MEDI-551 are shown in
Fig. 3, and PK parameters are summarized in Table 3.
MEDI-551 exhibited nonlinear PK for all dose levels,
ranging from 0.1 to 10.0 mg/kg. A dose-proportional
increase in Cmax values was observed, but both the
AUC0-last and AUC0-inf values demonstrated more than
dose-proportional increases for all dose levels. Mean CL
decreased from 6.2 to 3.5 mL/kg/day when the dose of
MEDI-551 was increased from 0.1 to 10.0 mg/kg. For
MEDI-551 doses of 1.0 mg/kg or greater, parallel terminal
elimination phases and similar half-lives (11.3–13.5 days)
were observed, whereas the terminal elimination half-life
of MEDI-551 was shorter at lower doses (6.8 and 7.1 days
for the 0.1- and 0.3-mg/kg groups, respectively). The
mean Vss ranged between 53.7 and 71.6 mL/kg across the
dose groups.
Pharmacodynamics
A single IV administration of MEDI-551 at all dose
levels resulted in rapid and sustained decreases in the
number of circulating B cells in all subjects (Fig. 4;
Table 4). Higher doses of MEDI-551 were associated
with a greater proportion of subjects achieving B cell de-
pletion: two of four (50 %) subjects in the 0.3-mg/kgFig. 3 Pharmacokinetics of MEDI-551. Serum concentration-time profile ofdose group, five of six (83.3 %) in the 1- and 3-mg/kg
dose groups, and seven of seven (100 %) in the 10-mg/kg
dose group achieved dose depletion. In the 0.3-mg/kg,
1.0-mg/kg, 3.0-mg/kg, and 10.0-mg/kg dose groups, re-
spectively, the median times to B cell depletion were 43.5,
57, 29, and 28 days, with median durations of B cell deple-
tion of 14, 29, 119, and 231 days. The mean values for the
maximum observed B cell reduction from baseline were
89.7 %, 93.0 %, 93.4 %, and 98.3 % for the 0.3-mg/kg, 1.0-
mg/kg, 3.0-mg/kg, and 10.0-mg/kg dose groups, respect-
ively. The single subject who received MEDI-551 0.1 mg/
kg displayed B cell depletion kinetics similar to that of
subjects in the 0.3-mg/kg group. As expected, B cell
counts in the placebo group were variable, and no trend
over time was apparent (data not shown).
Day 85 CD20+ B cell counts were available for 23
MEDI-551-treated subjects and for three placebo sub-
jects. Day 85 CD20+ B cell counts in the MEDI-551
group ranged from 0 to 104.5 % of day 1 values, while
those in the placebo group ranged from 63.5 to 137.8 %
of day 1 values. Twenty-two subjects in the MEDI-551
group and two subjects in the placebo group partici-
pated in the LTFU period (Fig. 2). During the LTFU
period, 16 (72.7 %) MEDI-551-treated subjects exhibited
recovery of B cell counts to baseline levels. Among the
six MEDI-551-treated subjects for whom full B cell re-
covery was not observed, four (18.2 %) were released
from the LTFU period prior to full B cell recovery by
mutual agreement of the investigator and sponsor after
at least 18 months of follow-up, based on observed
trends in B cell recovery and clinical judgement; two
(9.1 %) withdrew consent (Fig. 2) and could not be fully
assessed for B cell recovery. The two placebo subjectsMEDI-551 following a single IV administration
Table 3 Pharmacokinetic parameters for MEDI-551
MEDI-551 dose, mean (SD) n Cmax, μg/mL AUC0-last, μg•d/mL AUC0-inf, μg•d/mL CL, mL/kg/d T½, day Vss, mL/kg
0.1 mg/kg 1 2.7 13.0 16.1 6.2 6.8 53.7
0.3 mg/kg 3a 8.0 (1.8) 45.7 (12.9) 50.6 (13.2) 6.2 (1.5) 7.1 (1.8) 58.9 (24.5)
1.0 mg/kg 5b 22.5 (7.1) 202.0 (79.2) 211.0 (77.0) 5.3 (2.2) 11.3 (3.7) 69.3 (11.4)
3.0 mg/kg 4c 83.6 (10.6) 781.0 (230.0) 789.0 (230.0) 4.1 (1.3) 11.3 (1.0) 63.4 (22.4)
10.0 mg/kg 6d 227.0 (43.0) 2840.0 (260.0) 2890.0 (267.0) 3.5 (0.4) 13.5 (1.1) 71.6 (8.2)
AUC0-inf area under the concentration-time curve extrapolated to infinity after dosing, AUC0-last area under the concentration-time curve from dosing to last
measurable time point, CL systemic clearance, Cmax maximum observed concentration, t½ terminal elimination half-life, Vss steady-state volume of distribution
an = 4 for Cmax
bn = 6 for Cmax
cn = 5 for t½
dn = 7 for Cmax
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counts that equaled or exceeded baseline counts at day
85 or at the first LTFU assessment. Subjects exited the
study after B cell repletion was achieved; as a result, the
number of subjects with available B cell data declined
during LTFU (Fig. 4). The prolongation of B cell deple-
tion in the 1.0-mg/kg group is likely related to the re-
duced number of subjects with data available at later
time points.
Circulating plasma cells, as measured by the PC gene
signature in whole blood, were reduced following MEDI-
551 administration (Fig. 5). Plasma cell gene signatures
were reduced to 25 to 50 % of baseline on day 3 and 8 to
20 % of baseline on day 29, with a greater degree of reduc-
tion observed with higher MEDI-551 doses. At day 85, theFig. 4 Effect of MEDI-551 on peripheral B cells. Median B cell counts over t
values. The data plotted represent only those subjects for which B cell cou
analysis in each group at each time point is tabulated below the graph. Th
cell repletionPC gene signature had partially recovered in the 0.1-, 0.3-,
and 1.0-mg/kg groups, but had declined further in the
higher-dose groups. After day 85, PC gene signatures re-
covered to near baseline levels. A reduction in the PC gene
signature was not observed for the placebo group (Fig. 5).
Disease assessments
Potential effects of MEDI-551 on skin thickness, as mea-
sured by the MRSS, were assessed as an exploratory end
point. The mean MRSS change from baseline to day 85
was -5.4 points (SD 4.2) in the combined MEDI-551
group and 2.3 points (SD 6.1) in the placebo group. In the
MEDI-551 dose groups, mean changes from baseline
ranged from -14.0 to -3.6, with no clear relationship to
dose level (Table 5).ime, by MEDI-551 dose. B cell counts are presented as % of day 1
nts are available at each time point. The number of subjects in the
is number declines over time as subjects exit the study following B
Table 4 Summary of B cell depletion activity of MEDI-551






Maximum B cell reduction,e
mean % (SD)
0.3 mg/kg 4 2 (50.0) 43.5 (30–57) 13.5 (0–27) 89.7 (3.9)
1.0 mg/kg 6 5 (83.3) 57.0 (29–67) 29.0 (0–209) 93.0 (10.2)
3.0 mg/kg 6 5 (83.3) 29.0 (7–85) 119 (0–154) 93.4 (10.9)
10.0 mg/kg 7 7 (100.0) 28.0 (3–86) 231 (30–264) 98.3 (3.2)
aDefined as ≥ 90 % reduction in B cell counts from the day 1 value
bAmong subjects who achieved B cell depletion
cDefined as the time to the first observation of ≥90 % reduction from the day 1 value
dDefined as the interval between the first and last observation of ≥90 % reduction in B cell count from the day 1 value. Subjects with B cell depletion at only a
single assessment had a duration of depletion of zero
eValues represent mean of the maximum degree of B cell reduction for subjects in the group, at any time after dosing, expressed as % reduction of day 1 values
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were also examined. Mean percent predicted FVC values
(standard deviation [SD]) in subjects who received
MEDI-551 were 81.6 % (18.8) at baseline (n = 24) and
81.2 % (18.9) at day 85 (n = 21) versus 87.9 % (10.9) at
baseline (n = 4) and 89.3 % (12.3) at day 85 (n = 4) in the
placebo group. Mean percent predicted DLco (SD) in
subjects who received MEDI-551 was 72.4 % (22.5) at
baseline and 65.8 % (23.6) at day 85 versus 69.8 % (30.2)
at baseline and 66.2 % (25.9) at day 85 in the placebo
group.
Discussion
In this phase I study of MEDI-551 in subjects with SSc,
single MEDI-551 doses from 0.1 to 10 mg/kg were safe
and well tolerated. Most subjects in both the MEDI-551
and placebo groups experienced TEAEs followingFig. 5 Effect of MEDI-551 on plasma cell signature in blood. Mean values atreatment, and most of the events were mild or moder-
ate in severity. Two SAEs, supraventricular tachycardia
in a subject on MEDI-551 0.3 mg/kg and subclavian vein
thrombosis in a subject on MEDI-551 1.0 mg/kg, were
deemed possibly related to MEDI-551 because of close
temporal association with dosing. However, both sub-
jects had relevant medical histories that may have con-
tributed to the events: the subject with supraventricular
tachycardia had a history of this condition, and the sub-
ject who experienced subclavian vein thrombosis had a
prothrombin 20210A mutation, which has been associ-
ated with increased risk of thrombosis [34]. The single
death reported in this study, which followed the occur-
rence of scleroderma renal crisis in a subject in the 3.0-
mg/kg dose group, was deemed unrelated to MEDI-551
treatment and was attributed to underlying disease. Clin-
ically significant abnormal ECG findings were observedre plotted. Bars represent standard error of the mean. PC plasma cells
Table 5 Summary of MRSS values by treatment
Treatment group n MRSS, mean (SD)
Day 1 Day 85 Change from day 1 to day 85
Placebo 4 22.8 (7.5) 25.0 (7.2) 2.3 (6.1)
MEDI-551 0.1 mg/kg 1 31.0 (NA) 17.0 (NA) -14.0 (NA)
MEDI-551 0.3 mg/ 4 23.5 (7.6) 17.3 (5.1) -6.3 (3.5)
MEDI-551 1.0 mg/kg 6 20.0 (9.8) 15.5 (8.7) -4.5 (1.5)
MEDI-551 3.0 mg/kg 6a 23.3 (12.8) 17.8 (13.1) -6.6 (3.0)
MEDI-551 10.0 mg/kg 7 24.0 (5.1) 20.4 (7.7) -3.6 (5.7)
Combined MEDI-551 24b 23.0 (8.7) 17.9 (8.5) -5.4 (4.2)
MRSS modified Rodnan skin score
aAt day 85, n = 5
bAt day 85, n = 23
Schiopu et al. Arthritis Research & Therapy  (2016) 18:131 Page 11 of 14in two MEDI-551-treated subjects; however, both had
relevant cardiac history as well as abnormal baseline
ECG findings.
Infusion-related reactions are a significant risk with
biologic agents. Rituximab and alemtuzumab, for ex-
ample, are associated with particularly high rates of
IRRs, with a 77 % incidence in oncology subjects and a
92 % incidence in multiple sclerosis subjects, respectively
[35, 36]. In the present study, IRRs were the most fre-
quently reported TEAE associated with MEDI-551, with
an incidence of 16.7 %. Premedication with antihista-
mines, acetaminophen, and glucocorticoids is often used
to reduce the risk of IRRs to therapeutic antibodies [37].
In fact, no subjects in this study who received such
premedication experienced an IRR. Type I (immediate)
hypersensitivity reactions (i.e., anaphylaxis) are especially
concerning, as they can be fatal if not diagnosed and
treated promptly. Rituximab is associated with a rela-
tively high frequency of these reactions (5–10 %) [38],
which may be related to its chimeric nature [39]. Such
reactions were not observed with MEDI-551 in this
study, with the caveat that the sample size was small.
B cell depletion therapy is associated with a reduction
of immunoglobulin levels and an increased risk of infec-
tion. Analysis of the long-term use of rituximab in a
large cohort of rheumatoid arthritis (RA) patients deter-
mined an event rate for serious infections of approxi-
mately four per 100 patient-years [40]. Although no
serious infections occurred during the present study,
given the small size and relatively short duration of the
study, an event rate similar to that of rituximab would
not be expected to result in a serious infection in study
participants. Rituximab has been linked to reduced im-
munoglobulin levels: in the large RA group, 22.4 % of
rituximab-treated patients developed low IgM and a
smaller proportion developed low IgG (3.5 %) or low
IgA (1.1 %) that persisted for at least 4 months [40]. In
the present study, seven patients with normal baseline
levels exhibited low IgG, IgA, and/or IgM levelsfollowing MEDI-551 treatment, and the duration of the
immunoglobulin reductions ranged from a single visit to
longer than 6 months. However, as other immunosup-
pressive medications were permitted during this study,
the effects on immunoglobulin levels may not be com-
pletely attributable to MEDI-551.
A low risk of progressive multifocal leukoencephalo-
pathy (PML) has been associated with rituximab use in
patients with autoimmune disease [41, 42]. Similarly,
late-onset neutropenia has been reported following ri-
tuximab therapy, although the risk appears to be some-
what less in patients with autoimmune disease (4 %) [43]
than in oncology (8–27 % incidence rate from six stud-
ies) [44]. The present study, a small, single-dose phase I
study, was not designed to assess these rare SAEs. How-
ever, no cases of PML or neutropenia were observed fol-
lowing MEDI-551 treatment.
MEDI-551 displayed nonlinear PK characterized by
slower clearance at higher doses (≥1.0 mg/kg), suggest-
ing saturation of a clearance mechanism. The terminal
elimination half-life approached 2 weeks at the highest
dose tested (10 mg/kg), similar to numerous other thera-
peutic monoclonal antibodies [45].
In this study, MEDI-551 exhibited durable PD effects
in which circulating B cells (as measured by immuno-
cytochemistry/flow cytometry) and PCs (as measured by
the PC gene signature) [28] were depleted. The time to
onset, duration, and degree of depletion with MEDI-551
were dose dependent. The hypothesized roles of B cells
in SSc pathogenesis have been discussed in the literature
[6–9], and the implications for B cell depletion by
MEDI-551 are clear. The significance of the depletion of
PCs with MEDI-551 is not clear in relation to the patho-
physiology of SSc and to a potential treatment effect.
Autoantibodies produced by PCs are found in most SSc
patients, and some have been shown to have profibrotic,
pro-inflammatory, or other effects suggestive of a patho-
genic role in the disease [8]. The effect of CD20-
targeting agents such as rituximab on autoantibody
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is associated with reduction in pathogenic autoantibody
titers in autoimmune disease [46], suggesting that rituxi-
mab does affect some antibody-producing cells. Add-
itionally, studies in transgenic mice identified a subset of
short-lived PCs that reside in the spleen and lymph
nodes (as opposed to bone marrow), express CD20, pro-
duce autoantibodies, and are sensitive to rituximab [47].
On the other hand, CD20-targeted B cell depletion has
also been reported to spare PCs in patients with auto-
immune disease treated with rituximab [48, 49] and in
mice [50], and response to rituximab is reduced in pa-
tients with RA with higher levels of a plasmablast-
specific marker, IgJ [51]. Relative to CD20, CD19 is
expressed on a broader range of B cell subsets, including
earlier-stage precursor cells and later-stage differentiated
cells, such as plasmablasts and some PCs [52, 53]. Fur-
ther research is needed to understand the contributions
of PCs to disease processes and to establish the differ-
ence, if one exists, in the therapeutic effect of CD20-
depleting versus CD19-depleting agents.
We previously reported analyses of B cell and PC gene
signatures in serial skin biopsy samples obtained before
and after treatment from subjects in this study, which
showed a PD effect of MEDI-551 on both cell types in
affected skin [28]. It is not yet clear whether the B cell
or PC tissue infiltrates observed in the skin and lungs of
SSc patients [11–15] contribute to the pathophysiology
of SSc. Potential mechanisms for the contribution of
tissue-localized B cells to disease pathology have been
proposed, including antigen-presenting cell function and
cytokine secretion [54, 55]. Interestingly, a recent study
showed that co-culture of B cells with dermal fibroblasts
from patients with SSc induces collagen production and
secretion of the profibrotic cytokines IL-6 and TGF-β1;
furthermore, this effect is dependent on direct contact
between B cells and fibroblasts [56, 57]. The demonstra-
tion of a PD effect of MEDI-551 on B cells in affected
skin raises the possibility of both systemic and local ef-
fects on disease processes.
The results of this study should be interpreted with re-
gard to certain study limitations. Although we observed a
potential trend of improvement in skin thickness in sub-
jects treated with MEDI-551 (and not in subjects who re-
ceived placebo), it is important to acknowledge the small
sample size and relatively short study duration. Addition-
ally, differences in baseline characteristics between the
treatment groups and the potential effect of concomitant
immunosuppressive therapy received by subjects during
the study are potentially confounding factors.
Conclusions
The safety and tolerability of a single escalating dose of
MEDI-551 in this population of subjects with SSc areencouraging and should be further studied in a larger
patient population. The PD effect on B cells, implicated
in the pathogenesis of this disease, provides rationale for
further study of MEDI-551 as a potentially disease-
modifying treatment for SSc.
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